MedTrace Logo

Exosomal Markers CD63 and CD9 in Vitiligo Before and After NB-UVB Therapy

NCT07796893 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-09-03

No results posted yet for this study

Summary

This study evaluated the expression of the exosomal markers CD63 and CD9 in the skin of patients with vitiligo and assessed changes in their expression after narrow-band ultraviolet B (NB-UVB) therapy. Twenty patients with vitiligo were included and received NB-UVB therapy for 3 months. Clinical disease activity and severity were assessed using the Vitiligo Disease Activity (VIDA) score and the Vitiligo Area Severity Index (VASI) before and after treatment. Before treatment, skin biopsies were obtained from lesional and perilesional skin. After treatment, skin biopsies were obtained from repigmented areas. The tissue specimens were evaluated histopathologically and by immunohistochemical staining for CD63 and CD9. Twenty normal skin specimens obtained during plastic surgery were used as healthy controls for comparison.

Conditions

Interventions

RADIATION

Narrow-Band Ultraviolet B (NB-UVB) Therapy

Participants with vitiligo received narrow-band ultraviolet B (NB-UVB) phototherapy for 3 months as the study intervention.

Sponsors & Collaborators

  • Amany El-Agamy Ibrahim El-Samadony

    lead OTHER

Principal Investigators

  • Amany El-Samadony, MSc · Tanta University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07796893 on ClinicalTrials.gov